Bronnert Anja, Bloomfield Peter M, Páramo Lilia Delgado, Lin Luling, Bloomfield Frank H, Cormack Barbara E
The Liggins Institute, Auckland, New Zealand.
Starship Child Health, Auckland, New Zealand.
PLoS One. 2025 Jul 9;20(7):e0327628. doi: 10.1371/journal.pone.0327628. eCollection 2025.
Nutrition is vital for preterm infant development. Vitamins play key roles as cofactors and gene regulators for metabolic and immune functions and are common added components of preterm infant nutrition. However, information on how vitamins impact in-hospital and neurodevelopmental outcomes is sparse. We aimed to determine the effect of fat- and water-soluble vitamin supplementation on clinical outcomes during neonatal care and later neurodevelopment of very preterm (≤32 weeks' gestation) and very low birth weight (≤1500 g) infants.
4 databases and 3 clinical trial registries were systematically searched for randomised controlled trials (RCTs). Two reviewers independently extracted data and assessed quality using the Cochrane Risk of Bias tool. Meta-analyses were conducted using a random-effect model for each vitamin subgroup. Data are presented as risk ratios [95% confidence intervals]. Of 4074 references identified, 43 studies were included in the review. Only 2 reported neurodevelopment at 2 years, and only 4 were studies of water-soluble vitamins (vitamin C, 3 studies; B12 and folate, 1 study). Survival free from neurodisability was not affected by supplementation of vitamin A (0.89 [0.74-1.08], n = 538, very low certainty of evidence) or vitamin D (0.76 [0.46-1.27], n = 78, very low certainty of evidence). The incidence of bronchopulmonary dysplasia was decreased by vitamins D (0.58 [0.41-0.83]) and C (0.59 [0.37-0.93]), very low certainty of evidence), retinopathy of prematurity was decreased by vitamins A (0.77 [0.61-0.98]) and E (0.10 [0.01-0.80]), very low to low certainty of evidence) and intraventricular haemorrhage was decreased by vitamin E (0.70 [0.52-0.92], moderate certainty of evidence). Culture-proven sepsis was decreased by vitamin A (0.88 [0.77-0.99], moderate certainty of evidence).
There are few and inconclusive data on the effect of vitamin supplementation in preterm infants on later neurodevelopment. Evidence for shorter-term outcomes is mostly of low certainty. Together with substantial heterogeneity in trial design, it therefore is difficult to recommend a specific supplementation regimen. Registry and Registry Number: This systematic review was prospectively registered on PROSPERO, ID CRD42023418552, available from https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023418552.
营养对早产儿发育至关重要。维生素作为代谢和免疫功能的辅助因子及基因调节剂发挥关键作用,是早产儿营养中常见的添加成分。然而,关于维生素如何影响住院期间及神经发育结局的信息稀少。我们旨在确定补充脂溶性和水溶性维生素对极早产儿(孕周≤32周)和极低出生体重儿(出生体重≤1500克)新生儿期护理期间的临床结局及后期神经发育的影响。
系统检索了4个数据库和3个临床试验注册库以查找随机对照试验(RCT)。两名研究者独立提取数据并使用Cochrane偏倚风险工具评估质量。对每个维生素亚组采用随机效应模型进行荟萃分析。数据以风险比[95%置信区间]表示。在识别出的4074篇参考文献中,43项研究纳入本综述。仅2项报告了2岁时的神经发育情况,仅4项是关于水溶性维生素的研究(维生素C,3项研究;维生素B12和叶酸,1项研究)。补充维生素A(0.89[0.74 - 1.08],n = 538,证据确定性极低)或维生素D(0.76[0.46 - 1.27],n = 78,证据确定性极低)对无神经残疾存活无影响。维生素D(0.58[0.41 - 0.83])和维生素C(0.59[0.37 - 0.93],证据确定性极低)可降低支气管肺发育不良的发生率,维生素A(0.77[0.61 - 0.98])和维生素E(0.10[0.01 - 0.80],证据确定性从极低到低)可降低早产儿视网膜病变的发生率,维生素E(0.70[0.52 - 0.92],证据确定性中等)可降低脑室内出血的发生率。维生素A(0.88[0.77 - 0.99],证据确定性中等)可降低经培养证实的败血症发生率。
关于补充维生素对早产儿后期神经发育影响的数据稀少且无定论。短期结局的证据大多确定性低。再加上试验设计存在大量异质性,因此难以推荐特定的补充方案。注册信息及注册号:本系统综述已在PROSPERO前瞻性注册,ID为CRD42023418552,可从https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023418552获取。